JP2021509012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021509012A5 JP2021509012A5 JP2020532596A JP2020532596A JP2021509012A5 JP 2021509012 A5 JP2021509012 A5 JP 2021509012A5 JP 2020532596 A JP2020532596 A JP 2020532596A JP 2020532596 A JP2020532596 A JP 2020532596A JP 2021509012 A5 JP2021509012 A5 JP 2021509012A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- synuclein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 16
- 102000003802 alpha-Synuclein Human genes 0.000 claims 10
- 108090000185 alpha-Synuclein Proteins 0.000 claims 10
- 208000018737 Parkinson disease Diseases 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 208000009829 Lewy Body Disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000002832 Lewy body dementia Diseases 0.000 claims 3
- 208000032859 Synucleinopathies Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 102000003799 beta-Synuclein Human genes 0.000 claims 1
- 108090000182 beta-Synuclein Proteins 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 102000004963 gamma-Synuclein Human genes 0.000 claims 1
- 108090001121 gamma-Synuclein Proteins 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023092397A JP7627300B2 (ja) | 2017-12-15 | 2023-06-05 | 抗αシヌクレイン抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720975.0A GB201720975D0 (en) | 2017-12-15 | 2017-12-15 | Anti-alpha synuclein antibodies |
| GB1720975.0 | 2017-12-15 | ||
| PCT/EP2018/084697 WO2019115674A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092397A Division JP7627300B2 (ja) | 2017-12-15 | 2023-06-05 | 抗αシヌクレイン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021509012A JP2021509012A (ja) | 2021-03-18 |
| JP2021509012A5 true JP2021509012A5 (enExample) | 2022-01-11 |
| JP7292279B2 JP7292279B2 (ja) | 2023-06-16 |
Family
ID=61009086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532596A Active JP7292279B2 (ja) | 2017-12-15 | 2018-12-13 | 抗αシヌクレイン抗体 |
| JP2023092397A Active JP7627300B2 (ja) | 2017-12-15 | 2023-06-05 | 抗αシヌクレイン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092397A Active JP7627300B2 (ja) | 2017-12-15 | 2023-06-05 | 抗αシヌクレイン抗体 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11261242B2 (enExample) |
| EP (1) | EP3724224A1 (enExample) |
| JP (2) | JP7292279B2 (enExample) |
| KR (1) | KR102789446B1 (enExample) |
| CN (1) | CN111479826B (enExample) |
| AR (1) | AR115192A1 (enExample) |
| AU (1) | AU2018382530B2 (enExample) |
| BR (1) | BR112020010504A2 (enExample) |
| CA (1) | CA3083199A1 (enExample) |
| CL (1) | CL2020001605A1 (enExample) |
| EA (1) | EA202091478A1 (enExample) |
| EC (1) | ECSP20039623A (enExample) |
| GB (1) | GB201720975D0 (enExample) |
| IL (1) | IL275187A (enExample) |
| MA (1) | MA51135A (enExample) |
| MX (2) | MX2020005691A (enExample) |
| MY (1) | MY205948A (enExample) |
| PE (1) | PE20201061A1 (enExample) |
| PH (1) | PH12020551007A1 (enExample) |
| SG (1) | SG11202004502SA (enExample) |
| TN (2) | TN2020000069A1 (enExample) |
| TW (2) | TWI801469B (enExample) |
| UA (1) | UA126295C2 (enExample) |
| UY (1) | UY38010A (enExample) |
| WO (1) | WO2019115674A1 (enExample) |
| ZA (2) | ZA202003542B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3583124A1 (en) | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| BR112021006123A2 (pt) * | 2018-10-19 | 2021-07-20 | Janssen Vaccines & Prevention B.V. | anticorpos anti-sinucleína |
| AU2020350769A1 (en) * | 2019-09-20 | 2022-03-31 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| WO2021113464A1 (en) * | 2019-12-04 | 2021-06-10 | Friedman Simon | Protein blocking assembly and methods of making and using |
| KR20240176098A (ko) * | 2023-06-14 | 2024-12-24 | 경상국립대학교산학협력단 | 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| JP4055579B2 (ja) | 2000-12-13 | 2008-03-05 | 大正製薬株式会社 | 新規抗体 |
| US7479482B2 (en) | 2001-11-21 | 2009-01-20 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| HUE035044T2 (en) | 2003-05-19 | 2018-05-02 | Prothena Biosciences Ltd | Truncated fragments of alpha-synuclein in Lewy-body disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| HUE025225T2 (en) | 2007-02-23 | 2016-02-29 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic diseases |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| JP5558834B2 (ja) | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置 |
| LT2282758T (lt) | 2008-04-29 | 2019-03-12 | Bioarctic Ab | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams |
| CA2746778C (en) | 2008-12-19 | 2019-04-23 | University Of Zurich | Human anti-alpha-synuclein autoantibodies |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CN102869680B (zh) | 2010-02-26 | 2016-10-05 | 生命北极神经科学公司 | 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用 |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| US9910049B2 (en) | 2014-09-11 | 2018-03-06 | Amprion, Inc. | Detection of misfolded amyloid beta protein |
| US20160077112A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of Misfolded Proteins |
| US10989718B2 (en) | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
| WO2012061786A1 (en) | 2010-11-05 | 2012-05-10 | Brandeis University | Ice cleaved alpha-synuclein a biomarker |
| DE102011008153B4 (de) | 2011-01-08 | 2018-08-09 | Aj Roboscreen Gmbh | Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein |
| SI2723379T1 (sl) * | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| BR112014010198B1 (pt) * | 2011-10-28 | 2022-12-06 | Prothena Biosciences Limited | Anticorpos humanizados que reconhecem alfa-sinucleína |
| DK2807188T3 (da) | 2012-01-27 | 2019-10-07 | Prothena Biosciences Ltd | Humaniserede antistoffer, der genkender alpha-synuclein |
| DK2857419T3 (da) | 2012-05-30 | 2021-03-29 | Chugai Pharmaceutical Co Ltd | Antigen-bindende molekyle til eliminering af aggregerede antigener |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| US11191832B2 (en) | 2013-11-19 | 2021-12-07 | Prothena Biosciences Limited | Monitoring immunotherapy of Lewy body disease from constipation symptoms |
| SI3071597T1 (sl) * | 2013-11-21 | 2020-11-30 | F. Hoffmann-La Roche Ag | Anti alfa-sinukleinska protitelesa in postopki uporabe |
| WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| WO2015179867A1 (en) | 2014-05-23 | 2015-11-26 | University Of South Florida | Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| CN107074938A (zh) | 2014-10-16 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 抗‑α‑突触核蛋白抗体和使用方法 |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| PT3341725T (pt) | 2015-08-25 | 2021-09-21 | Prothena Biosciences Ltd | Métodos para detetar alfa-sinucleína fosforilada |
| JP6976249B2 (ja) | 2015-11-23 | 2021-12-08 | サンガモ セラピューティクス， インコーポレイテッド | 免疫を工学操作するための方法および組成物 |
| WO2017176835A2 (en) | 2016-04-06 | 2017-10-12 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
| TW202309093A (zh) | 2016-06-02 | 2023-03-01 | 英商梅迪繆思有限公司 | 針對α-突觸核蛋白之抗體及其用途 |
| GB201611840D0 (en) | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
| WO2018039147A1 (en) | 2016-08-23 | 2018-03-01 | The Johns Hopkins University | THERAPEUTIC USES OF LAG3 THE α-SYNUCLEIN TRANSMISSION RECEPTOR |
| RU2019114679A (ru) | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| US20180134777A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (11D12) |
| US20180134775A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (7A11) |
| US20180134776A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (4H6) |
| JP2020511963A (ja) | 2016-12-12 | 2020-04-23 | ザ マイケル ジェイ． フォックス ファウンデーション フォー パーキンソンズ リサーチ | ヒトアルファ−シヌクレインに対する抗体 |
| CN110072888B (zh) | 2016-12-16 | 2023-07-18 | H.隆德贝克有限公司 | 药剂、用途和方法 |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| CA3049110A1 (en) | 2017-01-06 | 2018-07-12 | Abl Bio Inc. | Anti-.alpha.-syn antibody and use thereof |
| WO2018128722A1 (en) | 2017-01-09 | 2018-07-12 | California Institute Of Technology | Use of gut microbiota in the diagnosis and therapeutics of parkinson's disease |
| EP3583124A1 (en) * | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| JOP20190227A1 (ar) | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
| TW201901153A (zh) | 2017-05-16 | 2019-01-01 | 美商安培恩股份有限公司 | 折疊錯誤之ｔａｕ蛋白的檢測及檢測折疊錯誤之ｔａｕ蛋白的套組 |
| WO2018237338A1 (en) | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
-
2017
- 2017-12-15 GB GBGB1720975.0A patent/GB201720975D0/en not_active Ceased
-
2018
- 2018-12-13 KR KR1020207019487A patent/KR102789446B1/ko active Active
- 2018-12-13 MA MA051135A patent/MA51135A/fr unknown
- 2018-12-13 AU AU2018382530A patent/AU2018382530B2/en active Active
- 2018-12-13 MX MX2020005691A patent/MX2020005691A/es unknown
- 2018-12-13 TN TNP/2020/000069A patent/TN2020000069A1/en unknown
- 2018-12-13 EA EA202091478A patent/EA202091478A1/ru unknown
- 2018-12-13 JP JP2020532596A patent/JP7292279B2/ja active Active
- 2018-12-13 SG SG11202004502SA patent/SG11202004502SA/en unknown
- 2018-12-13 PE PE2020000707A patent/PE20201061A1/es unknown
- 2018-12-13 EP EP18829767.5A patent/EP3724224A1/en active Pending
- 2018-12-13 CN CN201880080854.1A patent/CN111479826B/zh active Active
- 2018-12-13 BR BR112020010504-0A patent/BR112020010504A2/pt unknown
- 2018-12-13 US US16/771,993 patent/US11261242B2/en active Active
- 2018-12-13 WO PCT/EP2018/084697 patent/WO2019115674A1/en not_active Ceased
- 2018-12-13 CA CA3083199A patent/CA3083199A1/en active Pending
- 2018-12-13 UA UAA202002941A patent/UA126295C2/uk unknown
- 2018-12-13 TN TNP/2021/000169A patent/TN2021000169A1/en unknown
- 2018-12-13 MY MYPI2020002453A patent/MY205948A/en unknown
- 2018-12-14 UY UY0001038010A patent/UY38010A/es not_active Application Discontinuation
- 2018-12-14 AR ARP180103657A patent/AR115192A1/es unknown
- 2018-12-14 TW TW107145283A patent/TWI801469B/zh active
- 2018-12-14 TW TW112114559A patent/TW202332692A/zh unknown
-
2020
- 2020-06-07 IL IL275187A patent/IL275187A/en unknown
- 2020-06-12 ZA ZA2020/03542A patent/ZA202003542B/en unknown
- 2020-06-14 PH PH12020551007A patent/PH12020551007A1/en unknown
- 2020-06-15 CL CL2020001605A patent/CL2020001605A1/es unknown
- 2020-07-13 MX MX2024013356A patent/MX2024013356A/es unknown
- 2020-07-14 EC ECSENADI202039623A patent/ECSP20039623A/es unknown
-
2021
- 2021-05-21 ZA ZA2021/03456A patent/ZA202103456B/en unknown
-
2022
- 2022-01-26 US US17/585,174 patent/US20220220192A1/en active Pending
-
2023
- 2023-06-05 JP JP2023092397A patent/JP7627300B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021509012A5 (enExample) | ||
| HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
| JP2016512551A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2020513791A5 (enExample) | ||
| JP2017522892A5 (enExample) | ||
| IL275223B1 (en) | Anti-alpha-synuclein antibodies | |
| JP2015504306A5 (enExample) | ||
| JP2020037555A5 (enExample) | ||
| HRP20120759T1 (hr) | Bispecifična veziva specifična između vrsta | |
| JP2014534242A5 (enExample) | ||
| HRP20231134T1 (hr) | Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu | |
| FI3328893T3 (fi) | Mesoteliinia ja cd3:a sitovia bispesifisiä vasta-ainekonstrukteja | |
| JP2019533719A5 (enExample) | ||
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| NZ595687A (en) | Anti-tnf-alpha antibodies and their uses | |
| RU2010150348A (ru) | Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применение | |
| JP2010524435A5 (enExample) | ||
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| RU2018146158A (ru) | Антитела | |
| UA108466C2 (en) | Antibody antagonises c-Met | |
| RU2008140947A (ru) | Антитела к egfl7 и способы их применения | |
| PE20231680A1 (es) | Anticuerpos anti-cd30l y usos de estos | |
| JP2013509158A5 (enExample) | ||
| JPWO2022046944A5 (enExample) |